newsfilter
← Latest News
GlobeNewswire·

Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths

- All three dose strengths of STS101, administered with improved 2nd-generation nasal delivery device were well-tolerated and achieved target pharmacokinetic profile - - Initiating SUMMIT Phase 3 efficacy trial to evaluate STS101 5.2 mg in the acute t